Skip to main content

Advertisement

SpringerLink
Log in

Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

The relationship between the expression of CD133 and fragile histidine triad (FHIT) or prognosis in Chinese colorectal adenocarcinoma is unknown and needs to be explored.

Material and methods

The samples of colorectal adenocarcinoma from 200 Chinese patients with follow-up were analyzed for the expression of CD133 and FHIT proteins by immunohistochemical method.

Results

CD133 was highly expressed in up to 42.0% (84/200) of this group of colorectal adenocarcinomas. The expression of CD133 was significantly higher in carcinoma than in normal (P = 0.0001) and in adenomatous mucosas (P = 0.004). CD133 positively corresponds to histological grade, clinical stage, regional lymphatic metastasis, and distant metastasis (all P < 0.05). The mean overall survival time was shorter in patients with CD133 high expression than in those with CD133 low expression (P = 0.0001). The expression of CD133 was inversely correlative with that of FHIT (r = −0.464, P = 0.0001) in colorectal adenocarcinoma. CD133 was an independent prognostic factor (P = 0.0001).

Conclusions

The expression of CD133 may be inversely correlated with the expression of FHIT. It is suggested that CD133 may play an important role in the evolution of colorectal adenocarcinoma and be considered as a potential marker for the prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  2. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021

    PubMed  CAS  Google Scholar 

  3. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965–969

    Article  PubMed  CAS  Google Scholar 

  4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401

    Article  PubMed  CAS  Google Scholar 

  5. Zhou L, Wei X, Cheng L, Tian J, Jiang JJ (2007) CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 117:455–460

    Article  PubMed  CAS  Google Scholar 

  6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988

    Article  PubMed  CAS  Google Scholar 

  7. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM (2007) Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol 85:149–157

    Article  PubMed  Google Scholar 

  8. Ricci-Vitiani L, Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115

    Article  PubMed  CAS  Google Scholar 

  9. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110

    Article  PubMed  Google Scholar 

  10. Vermeulen L, Todaro M, de Sousa MF, Sprick MR, Kemper K, Perez Alea M et al (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105:13427–13432

    Article  PubMed  CAS  Google Scholar 

  11. Hibi K, Sakata M, Kitamura YH, Sakuraba K, Shirahata A, Goto T et al (2009) Demethylation of the CD133 gene is frequently detected in advanced colorectal cancer. Anticancer Res 29:2235–2237

    PubMed  CAS  Google Scholar 

  12. Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A et al (2009) Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. CANCER GENOMICS PROTEOMICS 6:19–29

    PubMed  CAS  Google Scholar 

  13. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH et al (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15:2258–2264

    Article  PubMed  CAS  Google Scholar 

  14. Horst D, Kriegl L, Engel J, Jung A, Kirchner T (2009) CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034–2040

    Article  PubMed  CAS  Google Scholar 

  15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285–1289

    Article  PubMed  CAS  Google Scholar 

  16. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A (2008) Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99:1578–1583

    Article  PubMed  CAS  Google Scholar 

  17. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109

    Article  PubMed  CAS  Google Scholar 

  18. Wang DS (2009) Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng 28:897–902

    Google Scholar 

  19. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J (2009) Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 55:284–293

    Article  PubMed  Google Scholar 

  20. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J et al (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–597

    Article  PubMed  CAS  Google Scholar 

  21. Cao J, Chen XP, Li WL, Xia J, Du H, Tang WB et al (2007) Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition. World J Gastroenterol 13:1018–1026

    Article  PubMed  CAS  Google Scholar 

  22. Lü Y, Liu L, Zhao P (2008) Expression of nuclear factor-kappa-B/P65 and fragile histidine triad in colorectal carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 88:610–614

    PubMed  Google Scholar 

  23. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC et al (2000) Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 60:18–21

    PubMed  CAS  Google Scholar 

  24. Pichiorri F, Palumbo T, Suh SS et al (2008) Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 4:815–824

    Article  PubMed  CAS  Google Scholar 

  25. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120

    PubMed  CAS  Google Scholar 

  26. LaBarge MA, Bissell MJ (2008) Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 118:2021–2024

    PubMed  CAS  Google Scholar 

  27. Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E et al (2007) Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110:534–542

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

The authors report no conflicts of interest. The authors are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Health Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, China

    Hong Li

  2. Department of Pathology, Chinese People’s Liberation Army (PLA) General Hospital, 28 Fuxing Road, Beijing, 100853, China

    Po Zhao, Yang Lu & Yali Lu

Authors
  1. Hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Po Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yali Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Po Zhao.

Additional information

What is new in this paper?

CD133 is considered as an important cancer stem cell marker related to cancer occurrence and meatastasis and FHIT is also an important tumour suppressor gene marker that is recently raised to the guardian of the preneoplastic genome. The relationship between two important markers is unknown and needs exploring. This research first investigated the correlation between CD133 and FHIT, and found that the relationship between two markers was inversely significant and both markers might have prognostic significance in colorectal cancer.

The authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, H., Zhao, P., Lu, Y. et al. Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma. Int J Colorectal Dis 27, 1015–1020 (2012). https://doi.org/10.1007/s00384-012-1421-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-012-1421-y

Keywords

Search

Navigation